Hong Kong Stock Afternoon Review | The three major indices rose, and TechNet stocks strengthened, Ali rose nearly 7%; some domestic housing stocks rose, and Sunac China rose more than 9%
Photovoltaic solar energy stocks weakened, Follett Glass fell nearly 9%, and Xinyi Solar fell more than 8%; insurance stocks generally rose; China Taibao rose more than 2%, and China Life Insurance rose nearly 2%.
The quarterly adjustment of the MSCI Index excludes 15 Hong Kong stocks. The effective date is scheduled for early June
① Which individual stocks will MSCI China adjust quarterly? ② How much impact does the MSCI Index have on the market?
Futu Morning Post | The three major US stock indices hit new highs! Ultramicrocomputers and Nvidia explode together
“New Federal Reserve News Agency”: The Federal Reserve may still not cut interest rates until September; “Big Short” Michael Burry took a heavy gold position in the first quarter.
Hong Kong Stock Afternoon Review | Tech Index rose nearly 1%, TechNet stocks and biotech stocks rose higher, Bilibili rose more than 6%, and Laikai Pharmaceuticals rose more than 12%
Auto stocks rose more than 6%; Great Wall Motor rose more than 6%; NIO and Zero Sports Auto rose more than 5%; many coal stocks fell sharply, Yankuang Energy fell more than 6%, and Shougang resources fell nearly 6%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
三生製藥:2023 年度報告
巨子生物:二零二三年年報
昊海生物科技:2024年第一季度報告
復星醫藥:2024年第一季度報告
復銳醫療科技:2023年度報告
四環醫藥:2023年度報告
山東新華製藥股份:2024年第一季度未經審核的業績
美麗田園醫療健康:2023 年報
復星醫藥:二零二三年年報
山東新華製藥股份:2023年年報
現代牙科:2023年度報告
時代天使:2023年度報告
康哲藥業:股東週年大會通告
復星醫藥:董事會會議日期